drugset / Trial / NCT07533305
Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Phase 2
Not yet recruiting
50 enrolled
The First Affiliated Hospital of Henan University of Science and Technology
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy and safety of QL1706 combined with nab-paclitaxel and cisplatin in first-line therapy for patients with advanced or metastatic esophageal squamous cell carcinoma. QL1706 is a anti-PD-1 and anti-CTLA4 antibody.
Timeline
- Start
- 2026-05-01
- Primary completion
- 2028-06-30
- Completion
- 2029-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 125 mg/m2 | Intravenous |
| Subject | QL1706 | Monoclonal antibody | 5 mg/kg | Intravenous |